Compare CTRE & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTRE | PTGX |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9B | 9.5B |
| IPO Year | 2013 | 2016 |
| Metric | CTRE | PTGX |
|---|---|---|
| Price | $39.05 | $143.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 13 |
| Target Price | $42.40 | ★ $108.23 |
| AVG Volume (30 Days) | ★ 1.8M | 451.6K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.44% | N/A |
| EPS Growth | ★ 96.25 | N/A |
| EPS | 0.74 | ★ 2.35 |
| Revenue | ★ $476,393,000.00 | N/A |
| Revenue This Year | $5.97 | $874.25 |
| Revenue Next Year | $13.39 | N/A |
| P/E Ratio | ★ $53.19 | $63.62 |
| Revenue Growth | ★ 60.79 | N/A |
| 52 Week Low | $32.79 | $57.45 |
| 52 Week High | $43.62 | $160.81 |
| Indicator | CTRE | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 42.48 | 50.81 |
| Support Level | $38.28 | $127.98 |
| Resistance Level | $40.12 | $160.81 |
| Average True Range (ATR) | 0.78 | 5.32 |
| MACD | -0.00 | -1.38 |
| Stochastic Oscillator | 55.06 | 9.68 |
CareTrust REIT Inc is a self-administered, publicly traded REIT engaged in the ownership, acquisition, financing, development, and leasing of skilled nursing, seniors housing, and other healthcare-related properties. The company has one reportable segment consisting of investments in healthcare-related real estate assets. It generates revenues by leasing healthcare-related properties to healthcare operators under triple-net lease arrangements, in which the tenant is solely responsible for property-related costs. The company operates in Domestic and Foreign markets, with the majority of revenue coming from Domestic operations.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.